Paradigm Biocapital Advisors LP Arcellx, Inc. Transaction History
Paradigm Biocapital Advisors LP
- $2.62 Billion
- Q4 2024
A detailed history of Paradigm Biocapital Advisors LP transactions in Arcellx, Inc. stock. As of the latest transaction made, Paradigm Biocapital Advisors LP holds 4,371,601 shares of ACLX stock, worth $283 Million. This represents 12.7% of its overall portfolio holdings.
Number of Shares
4,371,601
Previous 800,000
446.45%
Holding current value
$283 Million
Previous $66.8 Million
398.35%
% of portfolio
12.7%
Previous 2.41%
Shares
9 transactions
Others Institutions Holding ACLX
# of Institutions
224Shares Held
45.1MCall Options Held
434KPut Options Held
433K-
Nea Management Company, LLC Timonium, MD3.75MShares$243 Million20.37% of portfolio
-
Black Rock Inc. New York, NY3.52MShares$228 Million0.0% of portfolio
-
Perceptive Advisors LLC New York, NY3.48MShares$225 Million8.84% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.33MShares$216 Million0.0% of portfolio
-
Ra Capital Management, L.P. Boston, MA2.79MShares$181 Million3.44% of portfolio
About Arcellx, Inc.
- Ticker ACLX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 43,819,200
- Market Cap $2.84B
- Description
- Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). It...